News Releases

March 30, 2020
Synlogic Provides Summary of Impact of COVID-19 on Clinical Program Progress and Operational Activities
CAMBRIDGE, Mass. , March 30, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines called Synthetic Biotic ™  medicines, today provided an update on its business operations and expected...
March 12, 2020
Synlogic Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
- Synlogic ended 2019 with approximately $127 million in cash and investments, which provides runway into 2022 - - Company will host a conference call at 5:00 pm ET today - CAMBRIDGE, Mass. , March 12, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic...
March 11, 2020
Synlogic to Present at Chardan's Virtual Microbiome Medicines Summit
CAMBRIDGE, Mass. , March 11, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that Richard Riese , M.D., Ph.D., Synlogic's chief medical officer, will present at the Chardan Microbiome Medicines Summit at Noon ET on Monday, March 16 th , 2020. This is a virtual event....
March 5, 2020
Synlogic Announces Fourth Quarter and Full Year 2019 Conference Call and Webcast
CAMBRIDGE, Mass. , March 5, 2020 /PRNewswire/ --  Synlogic, Inc.  (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its fourth quarter and full year 2019 financial results...
February 18, 2020
Synlogic Announces Participation in Upcoming Investor Conferences
CAMBRIDGE, Mass. , Feb. 18, 2020 /PRNewswire/ --  Synlogic (Nasdaq: SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic's president and chief executive officer, will participate in the following upcoming investor conferences: 9th Annual SVB Leerink Global Healthcare Conference on...
January 30, 2020
Synlogic Appoints Dr. Michael Burgess to its Board of Directors
CAMBRIDGE, Mass. , Jan. 30, 2020 /PRNewswire/ --  Synlogic, Inc ., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Michael Burgess ,   M.B., Ch.B., Ph.D., president of research and...
January 9, 2020
Synlogic Outlines Upcoming Milestones for Clinical Programs and Unveils New Preclinical Pipeline Programs
– First subject treated in SYNB1891 immuno-oncology study, data from monotherapy arm expected in 2020 – – Expansion of pipeline with new preclinical programs in secondary hyperoxaluria and maple syrup urine disease (MSUD) – – Phase 2 clinical trial of solid formulation of SYNB1618 in patients with...
December 11, 2019
Synlogic Bridging Study Data with Solid Oral Formulation of SYNB1618, a Synthetic Biotic Approach to Treat Phenylketonuria, Demonstrate Improved Tolerability over Early Liquid Formulation and Guide to Next Stage of Clinical Development
– Company expects to initiate Phase 2 clinical trial in patients with phenylketonuria in 1H 2020 – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 11, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines,...
November 25, 2019
Synlogic to Webcast Presentation at the Piper Jaffray 31st Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 25, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference at 11:30 am ET on Thursday,...
November 12, 2019
Synlogic Provides Program and Business Update and Reports Third Quarter 2019 Financial Results
–SYNB1618 solid oral bridging study ongoing and SYNB1891 immuno-oncology study open – – Company ends 3Q2019 with approximately $139 million in cash, cash equivalents and investments supporting projected runway through 2021 – – Management to host conference call and webcast at 5:00 pm ET today –...
November 5, 2019
Synlogic Announces Third Quarter 2019 Conference Call and Webcast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its third quarter 2019 financial results after the market...
September 30, 2019
Synlogic to Present at the Chardan 3rd Annual Genetic Medicines Conference
  CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 30, 2019-- Synlogic, Inc. (NASDAQ: SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7 at 4:15...
Displaying 13 - 24 of 115